Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units

Rhea-AI Filing Summary

Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube received an equity award in the form of restricted stock units. On the reported date, he acquired 17,250 shares of Intellia common stock through a grant, at a stated price of $0.00 per share.

The award is structured as restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, Dube’s directly held common stock position reported in this filing increased to 69,527 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Michael P

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		17,250	A	$0	69,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Intellia Therapeutics (NTLA) report for Michael P. Dube?

Intellia Therapeutics reported that Michael P. Dube received an equity grant of 17,250 restricted stock units. Each unit represents a contingent right to one share of common stock, increasing his directly held position to 69,527 shares after the award.

How many Intellia Therapeutics (NTLA) shares were granted to Michael P. Dube?

Michael P. Dube was granted 17,250 shares of Intellia Therapeutics common stock through an award. The filing classifies this as a grant or other acquisition, bringing his directly owned common stock holdings to 69,527 shares after the transaction.

What type of security did Michael P. Dube receive from Intellia Therapeutics (NTLA)?

Michael P. Dube received restricted stock units tied to Intellia’s common stock. Each restricted stock unit represents a contingent right to receive one share of Intellia common stock, according to the footnote describing the structure of this equity award.

Was the Intellia Therapeutics (NTLA) insider transaction a purchase or a grant?

The transaction reported for Michael P. Dube was a grant or award, not an open-market purchase. It is coded as an acquisition (transaction code A) reflecting an equity compensation grant of 17,250 restricted stock units at a stated price of $0.00 per share.

What is Michael P. Dube’s role at Intellia Therapeutics (NTLA) in this Form 4?

In this Form 4, Michael P. Dube is identified as an officer of Intellia Therapeutics, serving as Vice President and Chief Accounting Officer. The reported transaction reflects an equity compensation award related to his executive position at the company.